$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter
Wall Street brokerages expect Amedisys Inc (NASDAQ:AMED) to report $385.37 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Amedisys’ earnings, with the highest sales estimate coming in at $385.40 million and the lowest estimate coming in at $385.33 million. Amedisys posted sales of $361.60 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.6%. The company is scheduled to issue its next earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Amedisys will report full-year sales of $385.37 million for the current fiscal year, with estimates ranging from $1.52 billion to $1.55 billion. For the next financial year, analysts anticipate that the firm will report sales of $1.62 billion per share, with estimates ranging from $1.61 billion to $1.64 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Amedisys.
Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm had revenue of $378.80 million during the quarter, compared to analysts’ expectations of $380.80 million. During the same period in the previous year, the company earned $0.42 earnings per share. The firm’s quarterly revenue was up 5.0% on a year-over-year basis.
Several equities research analysts recently commented on AMED shares. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a report on Friday, September 15th. Jefferies Group LLC restated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a report on Thursday, October 12th. SunTrust Banks, Inc. restated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a report on Monday, October 9th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 12th. Finally, Royal Bank Of Canada restated a “hold” rating on shares of Amedisys in a report on Monday. Seven analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $56.20.
Amedisys (NASDAQ:AMED) opened at 49.35 on Friday. The firm has a 50 day moving average of $51.46 and a 200-day moving average of $55.04. Amedisys has a 52-week low of $34.58 and a 52-week high of $65.91. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of 42.18 and a beta of 0.87.
In other Amedisys news, insider David B. Pearce sold 1,000 shares of the business’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the transaction, the insider now owns 10,488 shares in the company, valued at approximately $524,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bruce D. Perkins purchased 2,000 shares of Amedisys stock in a transaction on Thursday, August 3rd. The shares were acquired at an average price of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now directly owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.00% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of AMED. Riverhead Capital Management LLC raised its stake in shares of Amedisys by 75.5% in the 2nd quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA raised its stake in shares of Amedisys by 2.3% in the 2nd quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new stake in shares of Amedisys in the 3rd quarter worth $205,000. CIBC Asset Management Inc bought a new stake in shares of Amedisys in the 2nd quarter worth $230,000. Finally, SG Americas Securities LLC raised its stake in shares of Amedisys by 48.7% in the 2nd quarter. SG Americas Securities LLC now owns 3,743 shares of the health services provider’s stock worth $235,000 after buying an additional 1,226 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “$385.37 Million in Sales Expected for Amedisys Inc (AMED) This Quarter” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/27/385-37-million-in-sales-expected-for-amedisys-inc-amed-this-quarter.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.